Twist Bioscience

Historical price data

Twist Bioscience's mission is to provide the foundational synthetic DNA tools that enable breakthroughs across life sciences. Founded in 2013, the company has achieved a paradigm shift from traditional 96-well plate synthesis to a proprietary, scalable silicon platform, leading to its public listing in 2018. Its strategy focuses on a diversified B2B model, serving as an innovation partner to pharmaceutical, agricultural, and diagnostic companies while expanding into high-growth adjacent markets like antibody discovery and next-generation sequencing (NGS). With a market cap of ~$2.7B, Twist is positioned as a critical enabler in the rapidly expanding synthetic biology ecosystem.

Proprietary silicon-based DNA synthesis platform that miniaturizes chemical synthesis onto a semiconductor chip, enabling high-throughput, low-cost, and high-fidelity production of synthetic genes, oligo pools, and libraries.

Twist competes with large, established players like GenScript, IDT, and Agilent in DNA synthesis and NGS, and with specialized CROs in antibody services. Its primary differentiation is its proprietary, scalable silicon platform, which offers superior throughput and cost structure for large-scale synthesis.